GT-02287
GBA-Parkinson's Disease
Key Facts
About Gain Therapeutics
Gain Therapeutics is a clinical-stage biotech leveraging its proprietary Magellan™ platform to discover novel allosteric small molecule therapies for disorders with high unmet medical need. Founded in 2017, the company's lead program, GT-02287, is a best-in-class candidate for GBA-Parkinson's disease currently in Phase 1 clinical studies. Its strategy focuses on modulating protein function through stabilization, destabilization, or degradation, moving beyond simple inhibition to address the root cause of complex diseases.
View full company profileAbout Gain Therapeutics
Gain Therapeutics is a clinical-stage biotech leveraging its proprietary Magellan™ platform to discover novel allosteric small molecule therapies for disorders with high unmet medical need. Founded in 2017, the company's lead program, GT-02287, is a best-in-class candidate for GBA-Parkinson's disease currently in Phase 1 clinical studies. Its strategy focuses on modulating protein function through stabilization, destabilization, or degradation, moving beyond simple inhibition to address the root cause of complex diseases.
View full company profileTherapeutic Areas
Other GBA-Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| GCase Activator | Vanqua Bio | Preclinical |